Acquisition synergies RMC Pharmaceutical Solutions was acquired by Syner-G BioPharma Group in 2023, creating a combined entity with expanded CMC, regulatory strategy, and quality management capabilities. This indicates cross-sell opportunities to existing Syner-G clients seeking integrated development and regulatory services across biotech and pharma stages.

Global regulatory reach The merged entity offers globally scalable CMC and regulatory services, enabling sales teams to position a broader, end-to-end solution to mid-size and emerging biopharma players pursuing international submissions and harmonized development pathways.

Advanced tech enablement Syner-G and RMC leverage a tech stack including IBM Cognos Analytics, SAP, SharePoint, and AI-oriented initiatives like 3D Intelligence and AI-augmented authoring. This can be leveraged in value propositions around data-driven development, faster regulatory timelines, and improved knowledge management for IND-to-NDA lifecycles.

Growth momentum With ongoing leadership hires and recognition as a top place to work, the group signals continuing growth and client trust. This presents an opening to target growing biotech portfolios that seek stable partners with a proven track record of customized, scalable services.

Mid-market focus Revenue in the $1M–$10M range and a personnel base aligned with mid-sized biotech firms suggest targeting small- to mid-cap biotechs and CRO-like clients that need full development-to-submission support, complemented by Syner-G’s regulatory and quality infrastructure.